peplomycin and Prostatic-Neoplasms

Topics: Antineoplastic Agents; Cisplatin; Estramustine; Humans; Ifosfamide; Male; Peplomycin; Prostatic Neoplasms

In a 44-year-old man with persistent back-pain for 3 months duration, radiological and echological investigations revealed prostatic mass lesion with multiple osteoblastic involvements. Transrectal biopsy to the prostate demonstrated pathohistologically poorly differentiated adenocarcinoma (Gleason's score 4-4:8). Serum ACP, ALP and IAP were elevated at the initial diagnosis pathologically. The clinical and pathological stage was D2, without metastasis to lung and liver. Combination chemo-endocrine therapy (methotrexate, adriamycin, pepleomycin, Estracyt and tegafur) with bilateral orchiectomies was performed exclusively as initial treatment. These consecutive treatments brought remarkable reduction of the prostatic mass lesion, decrease of tumor markers to normal range, rapid improvement of subjective symptoms and distinct decrease of abnormal activity in bone scintigram. More than 3 years survival was obtained, and normal performance-status was kept. Prostatic cancer in middle-aged adults is reviewed and discussed.

Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Doxorubicin; Estramustine; Humans; Male; Methotrexate; Nitrogen Mustard Compounds; Orchiectomy; Peplomycin; Prostatic Neoplasms; Remission Induction; Tegafur

A rare case of prostatic rhabdomyosarcoma in a 3-year-old child is presented. He received a multimodal treatment of chemotherapy including vincristine, cyclophosphamide, actinomycin-D plus adriamycin, and linac irradiation followed by total prostatectomy with segmental resection of bladder. Despite no viable sarcoma cells in the surgical specimen, he showed relapse 4 months later. By the combination of cisplatin, vinblastine and peplomycin (PVP therapy), the bulky mass in the pelvis rapidly reduced by 95%. Furthermore, cisplatin, etoposide and peplomycin (PEP therapy), instead of PVP therapy, were administered to the refractory disease. Although the residual tumor was salvaged after 7 courses of PEP therapy, abdominal dissemination and liver metastasis occurred 2 months postoperatively. The combined modality of vincristine, peplomycin, ifosfamide, methotrexate, adriamycin, melphalan plus nimustine, and irradiation of microtron were effective for the abdominal dissemination, but he died of cerebral hemorrhage 31 months after the start of treatment. We emphasize that more aggressive chemotherapy including cisplatin, etoposide and so on is required to manage the advanced, relapsed, or resistant cases compared to the usual modality of rhabdomyosarcoma.

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Humans; Male; Neoplasm Recurrence, Local; Peplomycin; Peptichemio; Prednisone; Prostatic Neoplasms; Rhabdomyosarcoma; Vincristine

Pulmonary toxicity was less frequent in pepleomycin treatment of squamous cell carcinoma than in bleomycin treatment. The tumor-regressing effect appeared at about day 10 of pepleomycin treatment, and at about day 21 of bleomycin treatment. The cumulative dose of pepleomycin to complete remission was smaller than that of bleomycin. Pepleomycin is effective against bleomycin-sensitive malignancies: squamous cell carcinoma and Hodgkin's disease. It is more effective than bleomycin against lymph node metastases. Pepleomycin may have a broader antitumor spectrum: prostatic carcinoma responded.

Topics: Antibiotics, Antineoplastic; Bleomycin; Drug Evaluation; Drug Resistance; Female; Head and Neck Neoplasms; Humans; Lymphoma; Male; Middle Aged; Neoplasm Metastasis; Peplomycin; Prostatic Neoplasms; Skin Neoplasms

Between August, 1986 and August, 1992, 16 combination chemotherapies with etoposide (100 mg/body, day 1-5), ifosfamide (50 mg/kg, day 1, 3, 5), peplomycin (5 mg/body, day 1-5) were performed on 13 patients with endocrine therapy-relapsed advanced prostatic cancer. Seven trials were performed on 5 patients who received DESP (diethylstilbestrol diphosphate) (500 mg/body, day 1-5) with the chemotherapy. In 9 trials performed on 9 patients who did not receive DESP, there was no response case. In 7 trials with DESP, one trial had a partial response (PR) (14%) and 4 remained objectively stable (stable) (57%). As to adverse effects, myelosuppression was observed in all trials but there was no lethal toxicity. The one-year survival rate of these patients treated with the chemotherapy alone and combined DESP were both about 20%. Therefore we should find a more effective treatment for endocrine relapsed prostatic cancer.

Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Orchiectomy; Peplomycin; Prognosis; Prostatic Neoplasms; Survival Rate

The effect of local hyperthermia on the prostate using 13.56 MHz radio frequency wave (RF wave) was reported. Firstly, temperature and blood flow of the prostate in normal dogs were measured during local hyperthermia. In most part of the prostate, the temperature reached over 42 degrees C, which was considered as favorable for the hyperthermia therapy. Blood flow of the prostatic tissue rose more slowly than that of muscle tissue. Secondly, the tissue concentration of anticancer agents after local hyperthermia was measured. There was a tendency that drug concentration in the prostate tissue after local hyperthermia was higher than that without local hyperthermia. Histological findings showed interstitial edema and congestion. As a clinical trial, 14 cases of prostatic cancer were treated with local hyperthermia after the administration of anticancer agents. Seven of them were fresh cases and the others were relapsed cases. After treatment, tumor size was reduced in 13 cases. According to "The Response Criteria for Urologic Tumor", one Complete Response, 3 Partial Response and 10 No Change cases were obtained. There was no tumor progression. As for side effects, bone marrow suppression, loss of appetite, diarrhea and skin burns were noted. However, these side effects were mild, and did not interrupt the treatment. Local hyperthermia of the prostate after systemic chemotherapy could be carried out safely and effectively in patients with prostatic cancer.

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Bleomycin; Cisplatin; Combined Modality Therapy; Dogs; Etoposide; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostate; Prostatic Neoplasms

Between September 1982 and May 1984, combination chemotherapy with cis-platinum, peplomycin and adriamycin was administered to 12 patients with histologically confirmed adenocarcinoma of the prostate and progressive disease with evaluable parameters. Cis-platinum (CDDP) 20 mg/sqm was administered intravenously on Days 1-5, peplomycin 5 mg/sqm by 24-hour continuous drip infusion on day 1-5 and adriamycin 25 mg/sqm on Day 1. This course was repeated every 28 days. The dose and schedule were modified by hematologic toxicity or other side effects. One patient refused therapy because of severe nausea and vomiting; therefore 11 patients were eligible for response evaluation. Of the 11 patients, two had a documented PR, five had SD and four had PD. Ten patients whose disease eventually progressed received a second line of therapy consisting either of estramustine or estrogen. Of these ten patients, 6 had a documented PR, one had SD and three had PD. It is concluded that this combination chemotherapy regimen may prime advanced prostatic cancer to respond to hormonal therapy, even though it has only a limited effect on advanced prostatic cancer.

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Estramustine; Estrogens; Humans; Male; Middle Aged; Peplomycin; Prostatic Neoplasms

The present study was designed to investigate the efficacy of various combinations of chemotherapeutic agents in the treatment of prostatic cancer in a group refractory to antiandrogenic therapy (Group 1) and in a previous untreated group (Group 2). Therapeutic combinations of Estracyt (E) + Peplomycin (P) + Doxorubicin (Do) and P + Do + 5 FU (F) in Group 1 and E + P, Honvan (Ds) + P and E in Group 2 were carried out. The main objectives of this study were estimations of the efficacy of E and P in relation to the refractory cases of Group 1 and the efficacy of the combination E + P, in Group 2. This is the first such prospective, randomized, controlled study to be carried out in Japan in relation to prostatic cancer. The results obtained in the present study indicated that chemotherapeutic regimens including E provide some enhanced efficacy, but that the efficacy with regard to refractory cases is poor (23.1-27.3%), as has been reported of studies conducted in the USA and Europe. With regard to previously untreated cases, the E + P regimen achieved a relatively higher response rate than the other treatments (72.7 vs 44.5 or 50.0%). In the comparison of survival times and survival curves, there were no statistically significant differences among the various treatment subgroups. A comparison of survival curves revealed the interesting finding that the PAP-related response showed a clear correlation to the survival curves of Group 2 patients.

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Diethylstilbestrol; Doxorubicin; Estramustine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Peplomycin; Prospective Studies; Prostatic Neoplasms; Random Allocation

Topics: Adult; Aged; Bleomycin; Clinical Trials as Topic; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Peplomycin; Prostatic Neoplasms; Suppositories; Urinary Bladder Neoplasms

Primary squamous cell carcinoma (SCC) is an uncommon tumor of the prostate gland. A 65-year old man complained of obstructive symptoms.. Transrectal palpation and diagnostic imaging indicated an ordinary adenocarcinoma, although serum prostate-specific antigen (PSA) was normal. Biopsy specimens revealed SCC with the serum SCC antigen elevated. The patient was treated with pelvic irradiation and systemic administration of cis-platinum and peplomycin, which resulted in shrinkage of the cancer.. No evidence of recurrence has been seen for 18 months.

Topics: Aged; Antibiotics, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Humans; Magnetic Resonance Imaging; Male; Peplomycin; Prostatic Neoplasms; Radiation-Sensitizing Agents; Tomography, X-Ray Computed

The sensitivity of a hormone-independent human prostatic carcinoma cell line (PC-3) to chemohyperthermia was evaluated in vitro. The anticancer drugs used here were vincristine sulfate (VCR), peplomycin sulfate (PLM) and cis-diamminedichloroplatinum (CDDP). To evaluate cytotoxicity in short-term treatment, an inhibitory test on cell survival was more useful than a test on cell proliferation. With the inhibitory test on cell survival, the relationship of the administration method was examined to obtain better cell cytotoxicity, i.e., the cells were exposed to 1) the drug and heat at 43 degrees C simultaneously, 2) the drug followed by heat, or 3) heat followed by the drug. The combined treatment with drug and heat simultaneously produced more pronounced cytotoxicity than the treatment with heat followed by drug administration. The combined effect did not result from exposure to the drug followed by heat. Of the three drugs, the action of VCR and CDDP was potentiated with heat, but PLM was not.

Topics: Bleomycin; Cell Division; Cell Survival; Cisplatin; Humans; Hyperthermia, Induced; Male; Peplomycin; Prostatic Neoplasms; Temperature; Tumor Cells, Cultured; Vincristine

Effects of chemotherapy to endocrine therapy (castration with estrogen/antiandrogen)-relapsed (24 cases) or endocrine therapy-resistant (14 cases) prostate cancer were compared. Pretreatment clinical stages in these groups were stage D1 (3 cases) and D2 (35 cases). Regimens of chemotherapy in this study were as follows: cis-platinum (CDDP) (1 case), phosphamide (3 cases), combination of vincristine, phosphamide and peplomycin (5 cases), combination of cyclophosphamide, adriamycin (ADM) and CDDP (8 cases) and combination of phosphamide, ADM, and CDDP (21 cases). Response to chemotherapy and subsequent survival in these two groups were examined. When evaluated at 3 months after the start of the chemotherapy, partial response and stable cases were 50% and 36% in endocrine therapy-relapsed and -resistant groups, respectively. Because the worse performance status contained more cases in the endocrine therapy-resistant group, the response was compared at the same base of performance status, and the response was almost equal in the two groups. Survival in the endocrine therapy-relapsed group was better than that in the therapy-resistant group. When compared at the same base of performance status, the difference in survival time between the two groups was not evident. In conclusion, the response of chemotherapy was similar between endocrine therapy-relapsed and -resistant patients, and performance status was a main factor influencing the prognosis of endocrine therapy-refractory prostate cancer.

Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dimethoate; Doxorubicin; Drug Resistance; Estrogens; Humans; Male; Peplomycin; Prognosis; Prostatectomy; Prostatic Neoplasms; Vincristine

We performed hyperthermia concomitantly with the use of anticancer agents (etoposide and peplomycin) for the treatment of 13 patients with prostatic cancer. Seven of them were new cases and the others were recurrent ones. After intravenous administration of etoposide and peplomycin, hyperthermia was applied twice a week for 10 times in total. Clinical efficiency was evaluated by CT, ultrasound, prostatic biopsy. Tumor regression were observed in 12 cases. According to the General Rule for Clinical and Pathological Studies on Prostatic Cancer by Japanese Urological Association and the Japanese Pathological Society, one case of Ef2 and 5 cases of Ef1 were obtained with this treatment. Side effects caused by hyperthermia were urethral pain (1 case) and skin burning (1 case) noted.

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Evaluation Studies as Topic; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostatic Neoplasms

From January, 1986 to April, 1990, combination chemotherapy with ifosfamide (or cyclophosphamide), adriamycin, cis-platinum and peplomycin was performed in 15 patients with hormonally resistant metastatic adenocarcinoma. Three patients had partial response (PR) and 9 remained objectively stable (ST). The median response duration of PR + ST (12) was 5.7 months (range 2.8 to 18.0+). Three patients progressed while on this therapy. Of 8 patients with prior treatment of chemotherapy or chemo-hormonal therapy, 6 achieved an objective response (2 PR, 4 ST). Severe toxicities occurred in 2 patients. One died of lung fibrosis induced by peplomycin and the other received urinary diversion for persistent hemorrhagic cystitis. These results compare favorably with previous reports of chemotherapy treatment of metastatic prostatic cancer patients who failed on hormonal manipulation. However, careful treatment is needed for lung fibrosis and hemorrhagic cystitis.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Resistance; Humans; Ifosfamide; Male; Middle Aged; Peplomycin; Prostatic Neoplasms; Survival Rate

Selective intra-arterial infusion of ethylcellulose microcapsules containing anticancer drug exerts its therapeutic effects through infarction and sustained drug action (i.e., chemoembolization). Seven hundred and fifty-nine patients with malignant tumors of the liver (310), kidney (177), bladder (100), prostate (41), lung (39), pelvic organs (13), bone (4) and other (75) were treated with single or repeated chemoembolization using microcapsules delivered through percutaneous catheterization as a preoperative or palliative measure. Substantial tumor reduction of 50% was found in 18% of hepatoma, 19% renal cell carcinoma, 54% bladder carcinoma and 54% prostate carcinoma cases. Preoperative chemoembolization facilitated radical surgery for various cancers and significantly improved the survival of patients with locally invasive renal cell carcinoma and bladder carcinoma. Systemic toxic effects were mild, and all patients tolerated the treatment except for one who died of remote embolism to spleen and gallbladder. These results suggested that microcapsule chemoembolization can be successfully applied to a variety of tumors with low morbidity and mortality, and also combined with other treatments in multidisciplinary therapy.

Topics: Adolescent; Adult; Bleomycin; Capsules; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cisplatin; Embolization, Therapeutic; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Peplomycin; Prognosis; Prostatic Neoplasms; Urinary Bladder Neoplasms

Nineteen patients with hormonal refractory adenocarcinoma of the prostate were treated with ifosfamide (IFM) and the combination of vincristine, ifosfamide and peplomycin (VIP). Nine of them were treated with IFM, and nine with VIP, and one with IFM and also VIP. In the case of the IFM therapy, the over-all response rate was 0% by the Karnofsky's category of response, 20% by the response criteria of Shida et al., 50% by the National Prostatic Cancer Project (NPCP) criteria, and 0% by the response criteria of Koyama and Saito. In the case of the VIP therapy, the over-all response rate was 30% by the Karnofsky's category, 30% by the response criteria of Shida et al., 70% by the NPCP criteria and 20% by the response criteria of Koyama and Saitoh. The one-year survival rates of these patients treated with IFM and VIP were both about 20%. Only one patient treated with VIP therapy showed a partial response. Therefore, a more effective regimen for hormonal refractory adenocarcinoma of the prostate must be developed.

Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Humans; Ifosfamide; Male; Middle Aged; Peplomycin; Prognosis; Prostatic Neoplasms; Vincristine

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Cell Line; Cell Survival; Drug Screening Assays, Antitumor; Humans; Ifosfamide; Male; Peplomycin; Prostatic Neoplasms; Vincristine

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Etoposide; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostatic Neoplasms; Radio Waves

Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Capsules; Cisplatin; Embolization, Therapeutic; Humans; Infusions, Intra-Arterial; Male; Mitomycin; Mitomycins; Peplomycin; Prostatic Neoplasms

The sensitivity of a hormone-independent human prostatic carcinoma cell line (PC-3) to anticancer drugs was evaluated in vitro. The anticancer drugs used were vincristine sulfate (VCR), peplomycin sulfate (PLM) and 4-hydroperoxyisophosphamide (4-HIF), i.e., an form of ifosfamide (IFOS) in vivo. The inhibitory effect of 4-HIF alone and of the combination of VCR, 4-HIF and PLM (VIP) on the cell proliferation was almost the same. Furthermore, among the 6 groups treated with 2 of the 3 drugs mentioned above the most potent inhibitory effect was obtained in the group with combined treatment of 4-HIF plus PLM.

Topics: Bleomycin; Cell Division; Cell Line; Drug Combinations; Humans; Ifosfamide; Male; Peplomycin; Prostatic Neoplasms; Tumor Cells, Cultured; Vincristine

Prostate cancer: Considering the stagnation in chemotherapy of prostate cancer in recent years, the following experiments were carried out to determine their clinical value. Surgical specimens from 6 patients, 2 permanent cell lines (EB 33 and PC 93) originated from human prostate cancer and a tumor line serially transplanted in nude mice (PC-NCC) were subjected to chemosensitivity tests such as human tumor cloning assay (HTCA) and/or in vivo tumor growth curve experiments using nude mice. The possible chemosensitive drugs screened by using surgical specimens and PC-NCC tumor were cisplatinum (CDDP), bleomycin (BLM), 5-FU, vincristine (VCR), adriamycin (ADM) and methotrexate (MTX). Most of these drugs were also judged as "effective" by HTCA using a permanent cell line. The minimal discrepancy among them may lead to the conclusion that an in vitro assay using a cell line can substitute for the assay using surgical specimens which can not be obtained frequently. Partly based on the data obtained a chemotherapy regimen, VPM-CisCF, consisting of VCR, peplomycin, MTX, CDDP, cytosine arabinoside (Ara-C) and 5-FU, was designed. The effectiveness of this regimen was demonstrated experimentally. Testis cancer: Two different lines of experiments were performed. A human testicular cancer serially transplanted in nude mice was repeatedly exposed to CDDP in vivo to obtain hyposensitivity to this drug. The synergistic effect of CDDP and VP-16 was demonstrated in the tumor thus obtained. One of its mechanisms has been suggested by partial accumulation of cancer cells in the G1-S and G2-M phase in which CDDP exerts its potential effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Line; Cisplatin; Cytarabine; Etoposide; Fluorouracil; Male; Methotrexate; Mice; Mice, Nude; Neoplasm Transplantation; Peplomycin; Prostatic Neoplasms; Testicular Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vinblastine; Vincristine

Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil. Each cycle was repeated every 3 or 4 weeks. Of these patients, 9 were refractory to prior hormonal therapy and 8 (89%) achieved an objective response (3 partial, 6 stable) using the criteria of the U.S. National Prostatic Cancer Project. In the patients showing objective response, the duration was from 3 to 18 months with a median duration of 6 months. The survival periods from the initiation of chemotherapy in effective cases ranged from 6 to 20+ months with a median duration of 11 months. The major toxicity was myelosuppression, although no patients suffered life-threatening toxicity. We consider that VIP-DMF therapy is a useful regimen for the treatment of advanced prostatic cancer.

Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Ifosfamide; Male; Middle Aged; Mitomycin; Mitomycins; Peplomycin; Prostatic Neoplasms; Vincristine

Prostate cancer patients were treated with a basic therapy of intra-arterial injection of neocarzinostatin (NCS). This therapy was divided into three types of regimen: NCS intra-arterial injection alone, NCS intra-arterial injection + diethylstilbestrol (DES), and NCS intra-arterial injection + aclacinomycin A (ACR) + peplomycin (PEP). A comparative study was carried out on the clinical efficacies of these three regimens, and at the same time an investigation was made of the prognosis in the cases receiving NCS intra-arterial injection alone and NCS + DES. The clinical efficacy was found to be high in each of the three treatment groups in terms of subjective symptoms and laboratory findings, except for ALP. In the evaluation of efficacy on the basis of histological findings, the rates were 60.0% for NCS intra-arterial injection alone, 71.4% for NCS + DES, and 88.2% for NCS + ACR + PEP. Thus, all three of these treatment regimens gave good efficacy rates, but it is especially noteworthy that the combined chemotherapy regimen yielded the highest efficacy rate. On the other hand, the incidence of adverse reactions was much higher in the case of the combined chemotherapy regimen than in the other two regimens. In the patient group administered the NCS intra-arterial injection alone, the one-year survival rate was 75.0% and the 4-year survival rate was 25.0%, while in the NCS + DES treatment group the one-year survival rate was 87.5% and the 4-year survival rate was 37.5%. For individual patients, the correlation between the clinical efficacy and the prognosis was not strong. However, it was concluded that all three of the chemotherapy regimens are useful as forms of remission induction therapy.

Topics: Aclarubicin; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Diethylstilbestrol; Humans; Injections, Intra-Arterial; Male; Middle Aged; Naphthacenes; Peplomycin; Prognosis; Prostatic Neoplasms; Zinostatin

Topics: Aged; Bleomycin; Drug Evaluation; Humans; Male; Middle Aged; Peplomycin; Prostatic Neoplasms

Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; Humans; Ifosfamide; Male; Peplomycin; Prostatic Neoplasms; Vincristine

Continuous subcutaneous infusion of peplomycin was performed on 17 patients with metastatic prostate carcinoma, 9 of whom were refractory to conventional hormone therapy. Peplomycin was administered 5 mg daily through a newly-developed "microinfusion pump" for 14 consecutive days. This therapy was discontinued in 3 patients at the cumulative dose of 35, 35 and 55 mg. The mean cumulative dose was 84.7 mg. One patient who received 140 mg of peplomycin developed pulmonary fibrosis which was so mild that he recovered soon after the conservative therapy was instituted. There were no other episodes of pulmonary toxicities. Other major toxicities observed were anorexia (47%) and fever (41%). Of 15 patients who were evaluable with the response criteria of NPCP, 4 patients achieved objective partial regression (two for pulmonary metastases, one for bone metastases and the other for supraclavicular lymphnode metastases) and the other 11 patients remained stable. No progression of the disease was noted. Continuous subcutaneous infusion of peplomycin is advantageous over the bolus injection for increasing its anti-tumor activity as well as for decreasing its pneumotoxicity. It can also be performed for out-patients without difficulty. We believe this therapy should be incorporated in the multidisciplinary therapy of prostatic cancer.

Topics: Adenocarcinoma; Aged; Bleomycin; Drug Administration Schedule; Humans; Male; Middle Aged; Peplomycin; Prostatic Neoplasms

Topics: Aged; Bleomycin; Humans; Infusions, Parenteral; Lung; Lung Neoplasms; Male; Middle Aged; Peplomycin; Prostatic Neoplasms

Topics: Animals; Bleomycin; Humans; Male; Melanoma; Mice; Neoplasms, Experimental; Peplomycin; Prostatic Neoplasms

A relatively rare case of papillary adenocarcinoma of prostate is reported. The patient was a 49-year-old male. He presented with the chief complaints of micturition frequency, a feeling of residual urine and a burning sensation in urethra. There was no palpable abnormality in the prostate. Endoscopic examination revealed papillary tumors in the prostatic urethra and the anterior urethra, but no evidence of abnormality in the utricle. Both hematological examination and blood chemistry revealed no abnormalities; ACP, PACP and PAP were normal. The tumors were resected by TUR on March 8, 1982. Histopathological findings indicated papillary proliferation of single layer of columnar epithelium, with clear cytoplasm and nuclei with atypism distributed in the base. The tumors in the anterior urethra gave the same findings, and the diagnosis made was papillary adenocarcinoma which seemed to have originated from the prostatic duct. After operation, hormone therapy and chemotherapy with peplomycin were conducted. Eleven months after the operation, the remaining prostatic tissues including surgical capsule were resected as completely as possible. Histopathological findings revealed only atrophic prostatic tissues without any remaining tumor. The hormone therapy was discontinued. Presently, 19 months has elapsed since the first TUR. His micturition condition is good without evidence of recurrence or metastasis.

Topics: Adenocarcinoma, Papillary; Bleomycin; Combined Modality Therapy; Humans; Male; Middle Aged; Peplomycin; Prostatic Neoplasms; Urethral Neoplasms

Five mg of peplomycin was administered continuously for 24 hours by intravenous or subcutaneous infusion. Subcutaneous administration of peplomycin was performed done with the use of an SP-5 microinfusion pump made by the in Nipro Company. The plasma concentration after intravenous infusion was 0.0106 +/- 0.039 microgram/ml, while that after subcutaneous infusion was 0.131 +/- 0.037 microgram/ml. There was no statistical significance between the differences observed for intravenous and subcutaneous infusion.

Topics: Antibiotics, Antineoplastic; Bleomycin; Esophageal Neoplasms; Female; Humans; Infusions, Parenteral; Lymphoma; Male; Neoplasms; Peplomycin; Prostatic Neoplasms

Peplomycin, a new derivative of Bleomycin, was evaluated clinically for treatment of prostate cancer patients. Peplomycin was injected intramuscularly, 5 or 10 mg every other day, to 8 patients with prostate cancer. Total dose ranged from 30 to 200 mg. According to Karnofsky's criteria, only one case was I-B, other cases were in group 0. Pulmonary fibrosis, one of the major side effects of this drug, was experienced in 2 cases. This anticancer agent was injected directly into the prostate, 20 mg once a week for 5 weeks, to 2 patients who were refractory to estrogen treatment and had lower urinary obstruction for relief of local symptoms. One case was I-A, and the other was I-B. No severe side effect was observed. Serum concentration of Peplomycin after administration was measured by a bioassay. Serum levels of Peplomycin after a local injection of 20 mg and after one intravenous shot of 10 mg were almost equal.

Topics: Aged; Antibiotics, Antineoplastic; Bleomycin; Humans; Injections; Injections, Intramuscular; Male; Peplomycin; Prostatic Neoplasms

Peplomycin, a new anticancer agent, was produced as a side-chain derivative of bleomycin to reduce the incidence of pulmonary complications. Intramuscular injections of 5-10 mg of peplomycin were given 3 times a week to 35 patients with stages C and D disease. Patients were evaluated at the end of 12 weeks using the National Prostatic Cancer Project criteria. A response rate of 26% was achieved when peplomycin was used as the primary treatment. Prostatic cancer patients resistant to standard endocrine therapy had a 17% response rate to peplomycin therapy. Bone metastases were not influenced by this agent. The main side effects of peplomycin are fever and respiratory disturbances, but the incidence of these conditions is lower than that experience with bleomycin.

Topics: Acid Phosphatase; Aged; Antibiotics, Antineoplastic; Bleomycin; Humans; Male; Middle Aged; Peplomycin; Prostatic Neoplasms

Six patients with prostatic carcinoma entered this clinical trial using Pepleomycin, an analogue of Bleomycin, administered intramuscularly in a total dose of 120 mg. Two patients had an objective improvement lasting for three months. Also subjective improvement was observed in one patient. The main side effects were gastrointestinal disturbances, dermatologic symptoms and fever. However, pulmonary fibrosis, a well-known complication of Bleomycin therapy, could not be found.

Topics: Acid Phosphatase; Aged; Antibiotics, Antineoplastic; Bleomycin; Humans; Male; Peplomycin; Prostatic Neoplasms